NOBIVAC DUCAT

מדינה: אוסטרליה

שפה: אנגלית

מקור: APVMA (Australian Pesticides and Veterinary Medicines Authority)

מרכיב פעיל:

FELINE CALICIVIRUS; LIVE FELINE HERPES VIRUS

זמין מ:

INTERVET AUSTRALIA PTY LIMITED

INN (שם בינלאומי):

feline calicivirus+feline rhinotracheitis

טופס פרצבטיות:

MISC. VACCINES OR ANTI SERA

הרכב:

FELINE CALICIVIRUS VACCINE-VIRAL Active 4.6 PFU/dose; LIVE FELINE HERPES VIRUS VACCINE-VIRAL Active 4.8 PFU/dose

יחידות באריזה:

10 x single dose vial; 20 x single dose vials; 25 x single dose vial; 50 x single dose vial

סיווג:

VM - Veterinary Medicine

תוצרת:

INTERVET AUSTRALIA

קבוצה תרפויטית:

CAT | CAT - QUEEN | CAT - TOM | KITTEN

איזור תרפויטי:

IMMUNOTHERAPY

סממני תרפויטית:

FELINE CALICIVIRUS | FELINE RHINOTRACHEITIS | CALICIVIRUS (FELINE) | FCV | FELINE HERPESVIRUS TYPE 1 | FHV-1 | FVR | HERPESVIRUS 1 (FELINE) | HERPESVIRUS TYPE 1 (FELINE) | RHINOTRACHEITIS (FELINE)

leaflet_short:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: CAT: [FELINE CALICIVIRUS, FELINE RHINOTRACHEITIS]; Live vaccine for the active immunisation of cats to reduce the clinical signs caused by infection with feline calicivirus & feline herpes virus type 1.The safety of this product has not been tested in pregnant or lactating queens. See also SIDE EFFECTS & MANDATORY WARNINGS on lealet.

מצב אישור:

Registered

תאריך אישור:

2023-07-01

עלון מידע

Product Name:
APVMA Approval No:
NOBIVAC DUCAT
62997/133638
Label Name:
NOBIVAC DUCAT
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each single dose contains at least:
4.6 log
^
10 PFU
1
of live feline calicivirus F9 strain and
4.8 log
^
10 PFU
1
of live feline herpes virus type 1 G2620A strain.
1
PFU: Plaque-Forming Units
Claims:
Live vaccine for the active immunisation of cats to reduce the
clinical signs caused by
infection with feline calicivirus and feline herpes virus type 1.
Net Contents:
10 x single dose vials (1 mL after reconstitution).
20 x single dose vials (1 mL after reconstitution).
25 x single dose vials (1 mL after reconstitution).
50 x single dose vials (1 mL after reconstitution).
Directions for Use:
Restraints:
Contraindications:
Precautions:
The safety of these products this product has not been tested in
pregnant or lactating
queens.
Only healthy cats should be vaccinated and an adequate clinical
examination should be
made prior to inoculation. Sterile equipment should be used for
administration, but avoid
contamination of vaccine with traces of disinfectant or spirit. RLP APPROVED
Side Effects:
A slight, painful swelling may be observed at the injection site for
1-2 days. A slight
transient rise in temperature (up to 40°C) may occur for 1-2 days. In
some cases, general
discomfort, coughing, sneezing, transient lethargy and reduced
appetite may be observed
for a few days post-vaccination.
Dosage and
Administration:
USE ALL PRODUCT WITHIN 30 MINUTES OF RECONSTITUTION
The contents of one vial of reconstituted vaccine should be injected
subcutaneously.
Reconstitute immediately prior to use by the addition of 1.0 mL of
sterile phosphate buffer
or Water for Injection.
Primary vaccination
Vaccination may commence from 8-9 weeks of age. Kittens and cats
should receive two
vaccinations with an interval of 3-4 weeks. The final vaccination of
the kitten course should
be administered from 12 weeks of age onwards.
Revaccinati